Overview

  • Product name

    Anti-TPA Tissue Plasminogen Activator antibody
    See all TPA Tissue Plasminogen Activator primary antibodies
  • Description

    Rabbit polyclonal to TPA Tissue Plasminogen Activator
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IHC-Pmore details
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Recombinant fragment within Human TPA Tissue Plasminogen Activator (internal sequence). The exact sequence is proprietary.
    Database link: P00750

  • Positive control

    • WB: Human plasma; HEK-293T, Neuro-2a and PC-12 whole cell lysates. IHC-P: Human colon carcinoma and hepatoma tissues.

Properties

Applications

Our Abpromise guarantee covers the use of ab227069 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/3000. Predicted molecular weight: 63 kDa.
IHC-P 1/100 - 1/1000.

Target

  • Function

    Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration.
  • Tissue specificity

    Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
  • Involvement in disease

    Note=Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.
  • Sequence similarities

    Belongs to the peptidase S1 family.
    Contains 1 EGF-like domain.
    Contains 1 fibronectin type-I domain.
    Contains 2 kringle domains.
    Contains 1 peptidase S1 domain.
  • Domain

    Both FN1 and one of the kringle domains are required for binding to fibrin.
    Both FN1 and EGF-like domains are important for binding to LRP1.
    The FN1 domain mediates binding to annexin A2.
    The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site.
  • Post-translational
    modifications

    The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa.
    Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin.
    N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor.
    Characterization of O-linked glycan was studied in Bowes melanoma cell line.
  • Cellular localization

    Secreted > extracellular space.
  • Information by UniProt
  • Database links

  • Alternative names

    • Alteplase antibody
    • DKFZp686I03148 antibody
    • Plasminogen activator tissue antibody
    • Plasminogen activator tissue type antibody
    • PLAT antibody
    • Reteplase antibody
    • t PA antibody
    • T Plasminogen Activator antibody
    • t-PA antibody
    • T-plasminogen activator antibody
    • Tissue plasminogen activator (t PA) antibody
    • Tissue type plasminogen activator antibody
    • Tissue-type plasminogen activator chain B antibody
    • tPA antibody
    • TPA_HUMAN antibody
    • TPA1 antibody
    see all

Images

  • Anti-TPA Tissue Plasminogen Activator antibody (ab227069) at 1/2000 dilution + Human plasma at 30 µg

    Predicted band size: 63 kDa



    7.5% SDS-PAGE gel.

  • Paraffin-embedded human colon carcinoma tissue stained for TPA Tissue Plasminogen Activator using ab227069 at 1/250 dilution in immunohistochemical analysis.

  • Paraffin-embedded human hepatoma tissue stained for TPA Tissue Plasminogen Activator using ab227069 at 1/500 dilution in immunohistochemical analysis.

  • Anti-TPA Tissue Plasminogen Activator antibody (ab227069) at 1/1000 dilution + HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 30 µg

    Secondary
    HRP-conjugated anti-rabbit IgG

    Predicted band size: 63 kDa



    7.5% SDS PAGE gel.

  • Anti-TPA Tissue Plasminogen Activator antibody (ab227069) at 1/1000 dilution + Neuro 2a (mouse neuroblastoma cell line) whole cell lysate at 30 µg

    Secondary
    HRP-conjugated anti-rabbit IgG

    Predicted band size: 63 kDa



    7.5% SDS-PAGE gel.

  • Anti-TPA Tissue Plasminogen Activator antibody (ab227069) at 1/1000 dilution + PC-12 (rat adrenal gland pheochromocytoma cell line) whole cell lysate at 30 µg

    Secondary
    HRP-conjugated anti-rabbit IgG

    Predicted band size: 63 kDa



    7.5% SDS-PAGE gel.

References

ab227069 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab227069.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up